首页> 美国卫生研究院文献>Child and Adolescent Psychiatry and Mental Health >Recent developments and strategies in pediatric pharmacology research in the USA
【2h】

Recent developments and strategies in pediatric pharmacology research in the USA

机译:美国小儿药理学研究的最新发展和对策

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Research in pediatric pharmacology has undergone major changes in the last ten years, with an expansion in both publicly and privately funded activities. A number of pharmacokinetics studies and multi-site controlled efficacy trials have been conducted, so that treatment of children and adolescents can now be better informed and evidence-based. Regulatory financial incentives to industry in return for studies on drugs still covered by patent exclusivity have resulted in a substantial increase in pediatric research funded by pharmaceutical companies. In parallel, public funding has supported research on off-patent medications and other clinical important aspects of treatment, such as comparisons between active treatments, including non-pharmacological interventions. With greater interest by industry in pediatric research, the role of government funding agencies has been redefined to avoid duplication and ensure better integration of efforts and utilization of resources. The present review discusses some of the recent developments in pediatric pharmacology with focus on psychiatric medications.
机译:过去十年中,小儿药理学研究发生了重大变化,公共和私人资助的活动均有所扩展。已经进行了许多药代动力学研究和多部位对照功效试验,因此现在可以更好地为儿童和青少年提供治疗,并以证据为基础。工业上的管制性财政激励措施,以换取仍在专利专有权范围内的药物研究的回报,导致制药公司资助的儿科研究显着增加。同时,公共资金支持了对非专利药物和其他临床重要治疗方面的研究,例如积极治疗之间的比较,包括非药物干预。随着行业对儿科研究的更大兴趣,政府资助机构的作用已被重新定义,以避免重复并确保更好地整合工作和资源利用。本综述讨论了小儿药理学的一些最新进展,重点是精神科药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号